SCA Pharmaceuticals, LLC., Windsor, CT
Is SCA Pharmaceuticals, LLC. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B. The list does name SCA Pharmaceuticals in Windsor, CT, a close but not exact match shown below.
Does SCA Pharmaceuticals, LLC. hold a Connecticut pharmacy license?
No license with this exact name and city was found in the Connecticut Department of Consumer Protection file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The California State Board of Pharmacy also lists nonresident license NSF 141 for Sca Pharmaceuticals Llc, Windsor, CT, status Active, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0000045 for SCA Pharmaceuticals, LLC, WINDSOR, CT, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301011432 for SCA Pharmaceuticals LLC, Windsor, CT, status Active, as of Nov 10, 2026.
Has SCA Pharmaceuticals, LLC. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 2 FMD-145 letters (Oct 22, 2021 and Apr 17, 2025) for SCA Pharmaceuticals, LLC. Connecticut board disciplinary actions: not checked, because the Connecticut Department of Consumer Protection data this index reads gives license status only and does not include disciplinary actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- SCA Pharmaceuticals, LLC.
- Location
- Windsor, CT
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 4
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 13, 2026
- FDA Data Dashboard inspections
- 3 inspections: 1 OAI, 2 VAI; 6 published Form 483s
- Form 483 text on this page
- 4 Form 483s, 22 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as SCA Pharmaceuticals, LLC., a 503B facility, with 7 dated actions.
| Document | |||
|---|---|---|---|
| Mar 13, 2026 | Form 483 | 483 Issued 03/13/2026 | fda.gov |
| Apr 17, 2025 | FMD-145 letter | FMD-145 Letter Issued 04/17/2025 | Not linked by FDA |
| Dec 20, 2024 | Form 483 | 483 Issued 12/20/2024 | fda.gov |
| Nov 10, 2023 | Response to Form 483 | 483 Response Dated 11/10/2023 | FDA copy (archived) |
| Oct 20, 2023 | Form 483 | 483 Issued 10/20/2023 | FDA copy (archived) |
| Oct 22, 2021 | FMD-145 letter | FMD-145 Letter Issued 10/22/2021 | Not linked by FDA |
| Nov 19, 2019 | Form 483 | 483 Issued 11/19/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists SCA Pharmaceuticals, LLC, Windsor, CT (FEI number 3013736415), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Dec 20, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013736415 | 1252093 |
| Oct 20, 2023 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013736415 | 1221018 |
| Nov 19, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013736415 | 1111787 |
Form 483s FDA has published for this site
- Mar 13, 2026: Form 483 to SCA Pharmaceuticals, LLC, published May 8, 2026. fda.gov
- Dec 20, 2024: Form 483 to SCA Pharmaceuticals, LLC, published Jan 21, 2025. fda.gov
- Oct 20, 2023: Form 483 to SCA Pharmaceuticals, LLC, published Dec 19, 2023. fda.gov
- Nov 19, 2019: Form 483 to SCA Pharmaceuticals, LLC, published Feb 4, 2020. fda.gov
- Oct 24, 2018: Form 483 to SCA Pharmaceuticals, LLC, published Jan 17, 2024. fda.gov
- Apr 9, 2018: Form 483 to SCA Pharmaceuticals, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 22 numbered observations in all, across 4 inspections ending Nov 19, 2019 to Mar 13, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 17, 2026 to Mar 13, 2026: 3 observations
- Firm on the cover
- SCA Pharmaceuticals, LLC, 755 Rainbow Rd Ste B, Windsor, CT 06095-1024
- FEI number
- 3013736415
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 109 Holton Street Winchester, MA 01890
- Matched to this page by
- FEI number on the cover; linked from 503B list, actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed. Specifically,
A Your firm has initiated approximately 46 Excursion (EXC), representing <Redacted B4> batches of product, reports for microorganisms recovered from the ISO-5 critical zone in the Laminar Flow Hoods where sterile drug products are compounded. Since December 2024 organisms recovered included Staphylococcus species (epidermidis, hominis, capitis, haemolyticus), Bacillus simplex (clausii, infantis, circulans), Corynebacterium tuberculostearicum, Microcococcus luteus, and other organisms such as Kocuria, Peribacillus, Paenibacillus, Fictibacillus, Streptomyces, Cladosporium, Sphigmonas and Penicillium citrinum. These organisms have been characterized as either spore forming, or non-spore forming organisms recovered from either gloved fingertip, sleeve monitoring, active air, and/or passive air samples. ...
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
initiated due to contaminates observed that presents as material found on the plunger, floating particulate, or adhered to the stopper barrel. Despite this recurring pattern of particulate contamination, your firm has not:
• Conducted a thorough investigation to determine the definitive root cause(s) of the particulate failures.
• Implemented corrective and preventive actions (CAPA) that address the underlying cause(s) of particulate contamination.
• Demonstrated the effectiveness of any corrective actions taken to prevent the continued occurrence of intrinsic particulates in your drug products.
• Adequately justify the classification of"Major" for particulate contamination .
The repeated occurrence of intrinsic particulate failures without adequate investigation and effective CAPA demonstrates a failure to maintain your manufacturing process in a state of control.
Observation 3
Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Your firm's VAL-24-076-FR, Disinfectant Efficacy Study for <Redacted B4> against EM Isolates from the Connecticut Facility Located at 755 Rainbow Road, Windsor, CT 06095, Rev.1 established a <Redacted B4> dwell time when cleaning with <Redacted B4>. Your firm uses <Redacted B4> to clean and disinfect all classified areas. The following deficiencies were noted in V AL-24-076-FR executed in December 2024.
i. No evaluation of other organisms other than Bacillus subtilis (spizizenii) and the mixed culture of Bacillus altitudinis/pumilus/safensis. The firm has recovered other spore forming organisms from the ISO-5 sterile compounding core including: Penicillium citrinum, Streptomyces, Cladosporium and related organisms Peribacillus and Paenibacillus.
Bacillus altitudinis/pumilus/safensis. The firm has recovered other spore forming organisms from the ISO-5 sterile compounding core including: Penicillium citrinum, Streptomyces, Cladosporium and related organisms Peribacillus and Paenibacillus. ...
Inspection Dec 2, 2024 to Dec 20, 2024: 7 observations
- Firm on the cover
- SCA Pharmaceuticals, LLC, 755 Rainbow Rd Ste B, Windsor, CT 06095 -1024
- FEI number
- 3013736415
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 109 Holton Street Winchester, MA 01890
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been ah eady distributed.
Specifically,
A. Your firm failed to adequately assess and implement an effective connective and preventative action plan to remediate numerous findings of foreign material described as, cardboard, hair, fiber, or other, inside the <Redacted B4> tray packs containing un-filled sterile syringes. These syringe tray packs are received from <Redacted B4> syringe suppliers in configurations of <Redacted B4> and□ <Redacted B4> units. Since November 2023, your firm documented over 1200 supplier concern reports of foreign material found in these syringe tray packs and continued to use them as container closures in your manufacturing activities. Your firm continues to provide~~ supplier complaints to syringe suppliers regarding the foreign materials found in stenle synnge trays. Foreign material was reported in the following batches: The foreign material stemming from the syringe trays was a known issue found during your supplier qualification noted in the 2019 Questionnaire. ...
Observation 2
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, Your firm failed to adequately validate the manufacturing process for your sterile injectable products across multiple product lines, e.g., Vancomycin, Potassium Chloride, Norepinephrine, Potassium Phosphate, Phenylephrine, Diltiazem, and Oxytocin. From October 2023 until December 2024, your firm initiated approximately 24 manufacturing investigations classified as "Confirmed for potency OOS" representing 34 lots of sterile drug products.
Your firm fails to address the root causes of ''variable potency results" when using commercially available starting materials in order to ensure finished drug product produced are made consistently and remain within a state of control. Your firm failed to demonstrate the manufacturing process is capable of producing products that consistently meet established specifications and deliver a quality product.
Deviation #
Lnitiated
Product
Lot Number
Disposition
DEV-2023 -0573
10/31/2023 I Vancomycin ...
Observation 3
Written procedures are not for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically,
A. Your facility has not established a procedure for <Redacted B4> cleaning of the metal diffusers covering the HEPA filters within the <Redacted B4> Laminar Air Flow Hoods (LAFH) used to produce drug products that are purported to be sterile. Your firm produces approximately <Redacted B4> lots of drug products daily across <Redacted B4> ISO-5 LAFHs located in your clean room suite. For example, on 12/04/2024 vour operator manufactured the following two different drug products in ISO-5 LAFH <Redacted B4> with only a sanitization to the top, bar, walls, and deck of the LAFH, missing the front of the metal diffuser before producing the second drug product manufactured in the same <Redacted B4> LAFH. Your firm failed to adequately clean the LAFH to prevent potential cross-contammabon.
i Fentanyl Citrate 2mcg/ml and Bupivacaine HCl in 0.9% Sodium Chloride 250ml bag, Lot <Redacted B4>, Expiration 0 1/10/2025. ...
Observation 4
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.
Specifically,
A. Your firm fails to recertify your ISO-5 Laminar Air Flow Hoods when the metal diffusers, in front of the HEPA filters, are removed, cleaned front and back and then placed back inside the LAFH before resuming normal production of drug products purported to be sterile. According to your LAFH equipment manual, the metal diffuser should only be taken off by the certifier and your fnm performs the removal and attachment of the metal diffuser coverings without performing a risk assessment or scientific rationale for its removal and replacement by your sanitization operators. On 10/22/2024, your firm removed and cleaned the diffuser on LAFH <Redacted B4> and did not recertify the LAFH after this operation. Your firm then compounded Hydromorphone HCl 1 mg/mL in 0.9% Sodium Chloride 30 mL fill 35 mL Plungerless Syringe (30 mg/30 mL) Lot <Redacted B4> in LAFH <Redacted B4> on 10/22/2024.
B. ...
Observation 5
Batch production and control records do not include complete information relating to the production and control of each batch.
Specifically, your firm failed to adequately calculate the theoretical and actual batch yield steps at each phase of the production process for all sterile drug process. Your firm's calculated actual batch yield steps are not inclusive of all products produced during the manufacturing room. For example, during the production of <Redacted B4> HCl 80 mcg/mL in 0.9% Sodium Chloride 10 mL fill Syringe (800 mcg/10 mL) (KC), Lot: <Redacted B4> Expiration: 05/25/2025, <Redacted B4> units were filled of which 105 units were rejected before visual inspection. Your validated theoretical yield is <Redacted B4> your batch record. Your firm proceeded to the next production step when the actual yield failed to meet the validated range of <Redacted B4>
record. Your fom Qroceeded to the next production step when the actual yield failed to meet the validated range of[(b) (4) I.
Observation 6
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically, your operators were observed utilizing sterile goggles that are not designed to prevent microbial contamination. The sterile goggles have holes on the top and bottom allowing for potential particulates from operator's skin to have egress. The sterile goggles are a part of the sterile gowning used for operators in your cleanroom and when preparing sterile drug product in your <Redacted B4> ISO-5 Laminar Air Flow Hood. For example, on 07/16/2024, an excursion, EXC-2024-0173, report was initiated due to a recovery of 1 CFU/plate (specification <Redacted B4> identified as Staphylococcus epidermis and, separately, Staphylococcus warneri in the ISO-5 environment left, right, and center viable surface samples taken during the production of Phenvleohrine HCl 80 mcg/mL in 0.9% Sodium Chloride 10 mL fill Syringe (800 mcg/10 mL) (KC) Lot <Redacted B4> Expiration 01/12/2025.
Observation 7
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
Section 10.2.1.2 of SOP # LAB-007-W, Environmental and Personal Monitoring of Classified Areas, Revision: 37, states "A minimum of one (1) active viable air sample must be collected <Redacted B4> during compounding activities." Your firm's procedure is deficient in that you do not collect active viable air environmental monitoring samples that are representative of the beginning, middle, and end manufacturing process. For example, during the <Redacted B4> manufacturing process for sterile drug product Oxytocin 30 units added to 0.9% Sodium Chloride 500 mL Bag, Lot <Redacted B4>, Expiration 02/09/2025, only one (1) active viable air sample is collected during production activities. The same practice is utilized for the <Redacted B4> manufacturing production for Succinylcholine Chloride 20 mg/mL 10 mL fill Syringe (200 mg/10 mL) Lot: <Redacted B4> Expiration: 05-Dec-2024. There is no assurance the one active viable air sample is representative of the entire manufacturing process for the production of sterile drug products.
Inspection Sep 18, 2023 to Oct 20, 2023: 10 observations
- Firm on the cover
- SCA Pharmaceuticals, LLC, 755 Rainbow Rd Ste B, Windsor, CT 06095-1024
- FEI number
- 3013736415
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There is no quality control unit.
Specifically,
A. The firm’s investigation process is deficient in that the firm does not require identification of particulates found during the visual inspection process.
B. The firm’s visual inspection process governed by SOP ILP-001-W Product Inspection and Defect Classification” effective 2/22/2023 is deficient in that the SOP does not require the opening of an investigation after a failure of the 100% visual inspection. For example, in the last 6 months your firm has performed 100% visual inspection on approximately 3663 batches and approximately 783 failed 100% visual inspection. These batches were released without an investigation because the firm’s visual inspectional AQL passed. Furthermore, your SOP does not require an investigation after an AQL failure, unless a critical defect is found, or an investigation after a second 100% inspection failure. In the last 6 months you have had approximately 55 instances where you had a 100% visual inspection failure, AQL failure, a second 100% visual inspection failure, and a passing tightened AQL and an investigation is not always opened. ...
Observation 2
Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of manufacturing of the drug product.
Specifically,
The visual inspection % yield is not calculated or established in the batch record or is an established quality parameter. For example, the following batches were compounded and released.
A. Batch record for Hydromorphone HCL 1mg/mL in 0.9% Sodium Chloride 30mL fill 35mL Plungerless Syringe, Lot number 1223048865, shows 372 compounded units released to visual inspection and after the visual inspection rejection the amount of product released to labeling was 249 units, which had an approximate yield of 70%.
B. Batch record for Fentanyl 50mcg/mL 50mL bag, Lot number 1223048351, shows 286 compounded units released to visual inspection and after visual inspection rejection the amount of product released to labeling was 246 units, which had an approximate yield of 86%.
C. ...
Observation 3
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
A )Your SOP TM 008 “USP <788> Particulate Matter” is deficient in that after a failure of Test Method 1 (Light Obscuration Particle Count Test) than Test Method 2 (Microscopic Particle Count Test) is performed.
a. Your SOP states that If after a failure of Test Method 1 and a passing of Test Method 2, the product can be released and distributed without opening an investigation. For example, since 2019 there were approximately 38 instances where there was a failure of Test Method 1 and a Passing of Test Method 2 without opening an investigation. For example, see the chart below These products have been released and distributed.
X Lot Number Product Code
Method 2 Result
Product Name Method 1 Result
Method
2 Results ≥ 10 μm, ≥ 25 μm
Method 2 results ‐ ≤
Disposition of Lot
t
Compo und Date
BUD Route of Administra tion
# of Units compoun ded
3000 particles/con , ≤300
particles/cont
1223048899 F078140 Norepinephrine 4 mg contains s ulfites in ...
Observation 4
Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically,
A) There are no established procedures for preparing Spor-Klenz wipes used to sanitize all starting compounding materials, totes, and cleanroom equipment such as the firm’s ISO-5 Horizontal Laminar Flow Hoods, to ensure consistency and adequacy of cleaning. The firm prepares Spor-Klenz wipes used to sanitize starting materials and totes by adding an undefined amount of Spor-Klenz from a gallon container into a Contec non-sterile and low linting Sanotex Environmental Surface Wipes container. The firm prepares Spor-Klenz wipes used to perform nightly cleaning of the ISO-5 hoods by adding and an undefined amount of Spor-Klenz from a gallon container into a mop bucket containing an undefined amount of Berkshire Corporation sterile Gamma Wipes.
Klenz wipes used to perform nightly cleaning of the ISO-5 hoods by adding and an undefined amount of Spor-Klenz from a gallon container into a mop bucket containing an undefined amount of Berkshire Corporation sterile Gamma Wipes. ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not written.
Specifically,
A) Operators failed to follow techniques intended to maintain sterility of items and surfaces during aseptic operations. For example, on 18-SEP-2023, during production of lot 1223049390 Fentanyl 20mcg/mL in 0.9% Sodium Chloride 100mL Bags in bay CT0120, hood #7/2, Aseptic Assistant (PJ) was observed to touch items including totes, a chair, repeater pumps, gowning, and subsequently reached into the ISO-5 hood to provide additional starting materials and retrieve finished product without sanitizing hands or changing gloves. In addition, upon review of the firm’s Avigilon video recordings, Aseptic Assistant (PJ) touched the surface of a table were non-sterile paper and label items were located, as well as the paper batch record, and subsequently reached into the ISO-5 hood to provide additional starting materials and retrieve finished product without sanitizing hands or changing gloves. ...
Observation 6
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
The firm’s environmental monitoring practices of classified and aseptic processing areas do not ensure appropriate levels of environmental cleanliness. For example:
A) Personnel monitoring of gloved fingertips for Aseptic Assistants never occurs as part of the firm’s routine personnel monitoring program; however, Aseptic Assistants were observed reaching into ISO-5 hoods to stage starting materials and collect finished products during production.
B) The firm’s personnel monitoring action limit for the sleeves of Aseptic Assistants is > 10 colony forming units (CFUs); however, Aseptic Assistants were observed to reach into hoods during production. Since January 2020 there were 30 spore-forming microbial recoveries of < 10 CFUs on the sleeves of Aseptic Assistants. The firm failed to investigate and assess product impact for any of these spore-forming microbial recoveries.
C) The firm does not consider spore-forming bacteria recovered from classified environments as objectionable unless action levels are reached. ...
Observation 7
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.
Specifically,
The firm uses polypropylene totes to transfer all compound materials from non-classified environments into the ISO-7 compounding suite, which are further staged immediately adjacent to ISO-5 hoods. The totes appeared to have scratches, and some were observed with UPC stickers, on the bottom side of the tote and on lids, which and appeared to be shedding. In addition, in July 2023, the firm performed a tote study to determine bioburden found on the totes. Sampling results following the firm’s standard sanitization process and within the firm’s ISO-7 environment found 3% of samples collected yielded microbial recoveries. Of that, 60% were attributed to the genius Bacillus. Bacillus is a spore-forming bacterial microbe.
Observation 8
Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
Specifically,
Specifically, the firm failed to adequately investigate customer complaints. For example:
A) CUS-2023-0066, CUS-2023-0067, and CUS-2023-0068 were initiated on 25-Jul-23 regarding suspected super potency and three patients who experienced loss of consciousness, lethargy and inability to move, and issues moving legs, respectively, following administration of lot# 1223046077 (Fentanyl 2 mcg/mL and Ropivacaine HCl 0.2% in 0.9% Sodium Chloride 100 mL Bag). The firm’s investigation stated the complaints were not able to be confirmed; however, the firm failed to test returned products which were identified as integral. The investigation was approved and close by Quality Assurance 25-AUG-23, 23-AUG-23, and 28-AUG-23 respectively.
suspected super potency and three patients who experienced loss of consciousness, lethargy and inability to move, and issues moving legs, respectively, following administration of lot# 1223046077 (Fentanyl 2 mcg/mL and Ropivacaine HCl 0.2% in 0.9% Sodium Chloride 100 mL Bag). ...
Observation 9
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically,
A) Partially completed original GMP documents including but not limited to laboratory sheets and stability study sheets were found in the firm’s shred bins. The firm’s procedure, SOP QA0001 - Good Documentation Practices, prohibits this practice.
B) Multiple copies of blank fillable original GMP documents including but not limited to sterility worksheets and additional laboratory worksheets were found in the firm’s shred bins. The firm maintains GMP documents in MasterControl QMIS which allows authorized personnel to download documents to individual computer terminals with a 24-hour restriction; however, there are no restrictions on the number of copies that can be printed.
sterility worksheets and additional laboratory worksheets were found in the firm’s shred bins. ...
Observation 10
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Specifically,
Specifically, some of your drug product labels did not include the complete established name of the drug product, as the established name did not include the name of the salt (e.g., citrate, bitartrate, and hydrochloride) in addition to the base on the label.
For example,
A. Fentanyl 100 mcg/2 mL. The label does not include the full name Fentanyl Citrate
B. Norepinephrine 4 mg in 0.9% Sodium Chloride 250 mL bag. The label does not include the full name Norepinephrine Bitartrate.
C. Ketamine 100 mg/10 mL does not include the full name Ketamine HCL (Hydrochloride).
Inspection Oct 8, 2019 to Nov 19, 2019: 2 observations
- Firm on the cover
- SCA Pharmaceuticals, 755 Rainbow Rd Ste B, Windsor, CT 06095-1024
- FEI number
- 3013736415
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
The firm failed to adequately investigate the following:
A. There have been seven conformed failures for in-house sterility testing of finished sterile drug products since October 2018 using <Redacted B4> method for detection of fluorescence in individual microorganisms <Redacted B4>. All associated batches (1218003930, 1219007440, 1219008117, 1219008696, 1219009160, 1219009289, & 1219012541) were rejected; however, the investigations did not take into account the identity of the contaminating microorganism(s) to determine its source. ...
Observation 2
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
Specifically,
A. The firm failed to adequately qualify their method for Sterility Testing via <Redacted B4> in that during the method transfer, <Redacted B4> Performance Qualification for SCA Pharmaceuticals Windsor, CT (approved 11/28/2017, CT0051 & 01/08/2018, CT0052) the firm did not verify each product type via <Redacted B4> but instead only conducted testing using <Redacted B4> conducted by <Redacted B4> analysts. The firm has used this method routinely to test and release sterile drug product since <Redacted B4>.
B. The firm's method for sterility testing <Redacted B4> Procedure for Sterility Testing <Redacted B4> (SOP LAB-020-W), allows for <Redacted B4> with the <Redacted B4> ingredient for sterility testing.
Linked 483s whose text is not shown
- Oct 24, 2018: FDA document 112089: its numbered observations could not be read reliably from the PDF text.
- Apr 9, 2018: FDA document 112499: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
No license with this exact name and city was found in the Connecticut Department of Consumer Protection file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.
What this covers: The dataset gives each license’s status and status reason in the department’s words but lists no disciplinary actions, so Connecticut board actions are not checked.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NSF 141 | Nonresident Outsourcing Facility | Sca Pharmaceuticals Llc | Windsor, CT | Active |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0000045 | Outsourcing Facility-Distributor | SCA Pharmaceuticals, LLC | WINDSOR, CT | Closed |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301011432 | Pharmacy | SCA Pharmaceuticals LLC | Windsor, CT | Active |
Close but not exact matches
These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.
- SCA Pharmaceuticals, Windsor, CT: same city and state; names match only without the legal ending or through a dba name.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Connecticut Department of Consumer Protection license file
- California State Board of Pharmacy license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.